Nisa Investment Advisors LLC Sells 2,470 Shares of Zoetis Inc. $ZTS

Nisa Investment Advisors LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 1.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,529 shares of the company’s stock after selling 2,470 shares during the period. Nisa Investment Advisors LLC’s holdings in Zoetis were worth $24,879,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Nova Wealth Management Inc. bought a new position in Zoetis in the 1st quarter worth about $25,000. 1248 Management LLC bought a new position in shares of Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in shares of Zoetis in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC boosted its position in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares during the period. Finally, REAP Financial Group LLC boosted its position in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $146.14 on Monday. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $184.40. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market capitalization of $64.77 billion, a P/E ratio of 25.15, a P/E/G ratio of 2.35 and a beta of 0.90. The company has a fifty day moving average of $148.18 and a 200-day moving average of $153.57.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 earnings per share. The company’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ZTS shares. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. UBS Group dropped their price objective on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday, October 20th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Friday. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.